A PHASE 1/2 OPEN-LABEL STUDY IN PATIENTS WITH ARGINASE I DEFICIENCY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS AEB1102

Registry ID

CAEB1102-101A

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

AEGLEA BIOTHERAPEUTICS, INC

Start date

2018-07-26

Last update

2017-04-19

Conditions

• ARGINASE-1 DEFICIENCY

Related clinical trials

• PEACE (PEGZILARGINASE EFFECT ON ARGINASE 1 DEFICIENCY CLINICAL ENDPOINTS): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEGZILARGINASE IN CHILDREN AND ADULTS WITH ARGINASE 1 DEFICIENCY.
• AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFECTS OF INTRAVENOUS AEB1102 IN PATIENTS WITH ARGINASE I DEFECIENCY

View on source registry